News

Take our poll!

What can we learn from war trauma?

Welcome to the intersection of philosophy, psychology, and psychiatry.

In a first of its kind study, MDMA-assisted therapy successfully supported patients with PTSD.

Here are 5 processes to provide focus and empowerment for patients with PTSD.

Knowing the difference between one condition and another is critical, even when the precise diagnosis is unclear.

The challenge for clinicians lies in balancing the profound connection to patients’ suffering with the need to maintain personal resilience.

What did Einstein and Freud have to say about war, and how does it apply today?

The abysmal conditions in state mental hospitals in the 1940s were caused by 3 factors, none of which are now true. Let’s explore.

Travel can boost a clinician’s brain health, cultural intelligence, and creativity.

Here's something we can do physically to prevent suicide.

The ADHD Rx shortage is impacting children and their families. Here, a clinician shares how she supports her patients.

From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.

“If approved, KarXT would represent a new mechanism of action to treat schizophrenia, which would be the first new mechanism potentially in decades.”

What is new in research on posttraumatic stress disorder?

Write to us now to be part of our series focused on clinician wellness this month.

With the upcoming election and the rising risk of COVID, here’s how we can avoid physical and psychological trauma.

New positive pivotal phase 3 study data released on oral weekly risperidone for schizophrenia.

The data assess the extended efficacy of the treatment for up to 4 years.

The device is now available at 2 US clinics, with training and installation currently underway at several other locations.

The device is currently under clinical trial investigation as an adjunct treatment to standard of care therapy for experiential negative symptoms of schizophrenia.

New study results show evenamide as an add-on to antipsychotics for treatment-resistant schizophrenia significantly reduced disease severity.

"Together we will win..."

A psychiatrist reflects on a new year and anticipatory growth.

Will this medication make me gain weight? Researchers analyzed response to antidepressant treatment as a predictor of incident metabolic syndrome in a cohort of patients with depression.

Here’s to being curious in 2024!

Here are some updates from the world of psychiatry throughout the month of December.

What is new in research on seasonal affective disorder?

Psychiatric Times chats with new Mood Disorders Section Editor Gus Alva, MD, about his new role, his interest in mood disorders, and his love of psychiatry.